BioTime Inc (BTX)

3.19
AMEX : Health Care
Prev Close 3.23
Day Low/High 3.12 / 3.35
52 Wk Low/High 2.25 / 4.00
Avg Volume 378.50K
Exchange AMEX
Shares Outstanding 110.85M
Market Cap 358.06M
EPS 0.30
P/E Ratio 9.50
Div & Yield N.A. (N.A)

Latest News

Data From BioTime's OpRegen® Trial In Dry-AMD To Be Presented At ARVO On May 8

Data From BioTime's OpRegen® Trial In Dry-AMD To Be Presented At ARVO On May 8

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that a poster presentation based on data from its Phase...

BioTime Expands OpRegen® Clinical Trial In Dry-AMD With Opening Of First US Sites

BioTime Expands OpRegen® Clinical Trial In Dry-AMD With Opening Of First US Sites

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for...

BioTime, Inc. To Announce Fourth Quarter And Fiscal 2016 Results On March 16, 2017

BioTime, Inc. To Announce Fourth Quarter And Fiscal 2016 Results On March 16, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial...

BioTime Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary

BioTime Reports Pro Forma Gain On Deconsolidation Of OncoCyte Subsidiary

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the deconsolidation of OncoCyte Inc.

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the closing of its previously announced underwritten...

BioTime To Present At Two Upcoming Investor Conferences

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will be...

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the pricing of an underwritten public offering of...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced its intent to offer to sell shares of its common stock...

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda, Amgen and Regeneron Lead Premarket Biotech Movers

Acorda was soaring ahead of the market open, thanks to positive late-stage clinical trial results for levodopa.

BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., As General Counsel

BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., As General Counsel

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the appointment of Stephana Patton, Ph.

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement For Next-Generation Retinal Disease Therapy From University Of Pittsburgh Medical Center

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement For Next-Generation Retinal Disease Therapy From University Of Pittsburgh Medical Center

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the acquisition of global rights to ophthalmology-related...

BioTime To Present At Noble Capital Markets' Thirteenth Annual Investor Conference

BioTime To Present At Noble Capital Markets' Thirteenth Annual Investor Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that management will present a corporate overview at the...

Additional Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ARVO 2017

Additional Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ARVO 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, and its subsidiary, Cell Cure Neurosciences, Ltd.

BioTime And Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center In Jerusalem, Israel

BioTime And Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center In Jerusalem, Israel

BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences...

Ascendance Biotechnology Licenses The Right To Manufacture, Market And Sell Cytiva Cardiomyocytes

Ascendance Biotechnology Licenses The Right To Manufacture, Market And Sell Cytiva Cardiomyocytes

Today, Ascendance Biotechnology, Inc. ("Ascendance"), a leader in the commercialization of in vitro cell-based products and stem cell-related laboratory products, announced the execution of an Agreement with GE Healthcare...

BioTime Achieves Patient Recruitment Milestone In Renevia Pivotal Trial

BioTime Achieves Patient Recruitment Milestone In Renevia Pivotal Trial

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced that it has achieved an important patient enrollment milestone in...

BioTime To Present At Global Bioproduction Summit

BioTime To Present At Global Bioproduction Summit

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

BioTime Co-CEO Dr. Michael D. West To Deliver Plenary Presentation On The Field Of Induced Tissue Regeneration At World Stem Cell Summit

BioTime Co-CEO Dr. Michael D. West To Deliver Plenary Presentation On The Field Of Induced Tissue Regeneration At World Stem Cell Summit

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D.

Positive Early Data From BioTime's Renevia Pivotal Trial Presented At IFATS Meeting

Positive Early Data From BioTime's Renevia Pivotal Trial Presented At IFATS Meeting

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company with a focus on pluripotent cell-based technologies, announced details of positive data from its Renevia ® pivotal trial, reported via a...

BioTime Co-CEO Dr. Michael D. West To Chair Cell Therapy Track At World Precision Medicine Congress USA 2016

BioTime Co-CEO Dr. Michael D. West To Chair Cell Therapy Track At World Precision Medicine Congress USA 2016

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief Executive Officer Michael D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BTX, CARB, GHC, IPHS, PLPC, PXD, RP Downgrades: AIQ, EGL, ESIO, ETSY, MTRX, PKOH, RTRX, USAK Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

BioTime, Inc. Reports Third Quarter Results And Recent Clinical Progress

BioTime, Inc. Reports Third Quarter Results And Recent Clinical Progress

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today reported financial results for the third quarter ended September 30, 2016, and...

Data From BioTime's Renevia Pivotal Trial In HIV-Associated Facial Liopatrophy To Be Presented At The 14th Annual IFATS Meeting On November 17

Data From BioTime's Renevia Pivotal Trial In HIV-Associated Facial Liopatrophy To Be Presented At The 14th Annual IFATS Meeting On November 17

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia ® in 'run-in' patients with...

BioTime Appoints Industry Veteran Jim Knight As Senior Vice President, Head Of Corporate Development

BioTime Appoints Industry Veteran Jim Knight As Senior Vice President, Head Of Corporate Development

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice President, Head of...

BioTime, Inc. To Announce Third Quarter Results On November 3, 2016

BioTime, Inc. To Announce Third Quarter Results On November 3, 2016

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday,...

First Patient Cohort Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016

First Patient Cohort Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the first patient cohort of the Phase I/IIa clinical...

LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive MHealth Innovation

LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive MHealth Innovation

LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO), the leading provider of cloud-based solutions for clinical research.

BioTime To Present At The BIO Investor Forum

BioTime To Present At The BIO Investor Forum

BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor...